@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com 5 years ago
After 33 Exits in 5 Years, WI Seeks “More and Bigger” Startup Deals